The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Slides:



Advertisements
Similar presentations
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Advertisements

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,
Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
Nonmyeloablative conditioning for relapsed follicular lymphoma
Superior Survival after Autologous vs
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple.
Functional neutrophils from human ES cells
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
Figure 5 Number of AHSCT procedures for
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase by Jiří Pavlů,
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.
Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing.
Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman.
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD by Sarah A. Wall, Qiuhong Zhao, Martha.
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host.
Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple.
Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.
Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma  Anuj Mahindra, Brian Bolwell, Ronald.
Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Koji Sasaki, Gary Lu, Rima M. Saliba,
Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation  Willis H. Navarro, Fausto R.
Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation  Ajay K. Nooka,
Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence  Keshav.
by Kaiwen Chen, Matthew P. Cheng, Sarah P
Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib by Tracy E. Wiczer, Lauren B. Levine, Jessica.
What is quality in a transplant program?
Validation of the Hematopoietic Cell Transplantation–Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation  Muthu Veeraputhiran,
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
Volume 2(Supplement 1):46-49
Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma  Mark A. Fiala, Joseph D. Finney, Keith.
Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma  Tanya M. Wildes, Kristan M. Augustin, Diane.
Bridge to transplant following Bv+Bs regimen.
Eliane Gluckman  Experimental Hematology 
Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic.
Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.
Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia  SungNam Lim, Je-Hwan Lee, MD, PhD,
An algorithmic approach to FL
Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell.
TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
by Jan J. Cornelissen, and Didier Blaise
by Lapo Alinari, and Kristie A. Blum
Optimizing therapy for nodal marginal zone lymphoma
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Presentation transcript:

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma by Samantha M. Jaglowski, Craig C. Hofmeister, Patrick Elder, Sam Penza, Yvonne A Efebera, Don M. Benson, Steven M. Devine, and Leslie A Andritsos Blood Volume 120(21):4286-4286 November 16, 2012 ©2012 by American Society of Hematology

Overall survival by readmission within 100 days. Samantha M. Jaglowski et al. Blood 2012;120:4286 ©2012 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.